​

BioCryst Pharmaceuticals (BCRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BCRX Stock Forecast

BioCryst Pharmaceuticals stock forecast is as follows: an average price target of $9.00 (represents a 18.89% upside from BCRX’s last price of $7.57) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.

BCRX Price Target

The average price target for BioCryst Pharmaceuticals (BCRX) is $9.00 based on 1-year price targets from 15 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $7.00. This represents a potential 18.89% upside from BCRX's last price of $7.57.

BCRX Analyst Ratings

Buy

According to 15 Wall Street analysts, BioCryst Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for BCRX stock is 0 'Strong Buy' (0.00%), 12 'Buy' (80.00%), 3 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

BioCryst Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 06, 2024Gena WangBarclays$7.00$7.51-6.79%-7.53%
Aug 05, 2024Maury RaycroftJefferies$11.00$7.5146.47%45.31%
Nov 02, 2022Liisa BaykoEvercore ISI$16.00$12.3829.19%111.36%
Aug 23, 2022Gena WangBarclays$14.00$14.32-2.27%84.94%
Jan 10, 2022Ken CacciatoreCowen & Co.$25.00$14.7869.15%230.25%
Nov 03, 2021Brian ChengCantor Fitzgerald$21.00$12.4069.35%177.41%
Aug 09, 2021Maury RaycroftJefferies$19.00$17.657.65%150.99%

The latest BioCryst Pharmaceuticals stock forecast, released on Aug 06, 2024 by Gena Wang from Barclays, set a price target of $7.00, which represents a -6.79% decrease from the stock price at the time of the forecast ($7.51), and a -7.53% decrease from BCRX last price ($7.57).

BioCryst Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts--2
Avg Price Target--$9.00
Last Closing Price$7.57$7.57$7.57
Upside/Downside-100.00%-100.00%18.89%

In the current month, the average price target of BioCryst Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BioCryst Pharmaceuticals's last price of $7.57. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 04, 2024Piper SandlerOverweightOverweightHold
Nov 04, 2024Bank of America SecuritiesBuyBuyHold
Aug 06, 2024JMP SecuritiesOutperformOutperformHold
Aug 06, 2024BarclaysEqual-WeightEqual-WeightHold
Aug 05, 2024JefferiesBuyBuyHold
Jun 25, 2024Cowen & Co.BuyBuyHold
May 07, 2024JMP SecuritiesOutperformOutperformHold
Sep 18, 2023RBC CapitalOutperformUpgrade
Aug 04, 2023William BlairMarket PerformDowngrade
Aug 04, 2023Janney MontgomeryBuyUpgrade
Aug 04, 2023Raymond JamesMarket PerformOutperformUpgrade
Aug 04, 2023Wolfe ResearchUnderperformOutperformUpgrade
Aug 04, 2023Cowen & Co.Market PerformDowngrade
Aug 04, 2023Wells FargoEqual-WeightDowngrade
Aug 04, 2023OppenheimerPerformDowngrade
Aug 04, 2023JefferiesBuyUpgrade
Jul 13, 2023Bank of America SecuritiesBuyUpgrade
Feb 22, 2023Credit SuisseNeutralOutperformInitialise
Nov 02, 2022Evercore ISIOutperformUpgrade
Nov 02, 2022Wolfe ResearchUnderperformDowngrade
Nov 02, 2022Credit SuisseNeutralDowngrade
Nov 02, 2022Raymond JamesMarket PerformUpgrade
Aug 05, 2022BarclaysEqual-WeightEqual-WeightHold
Dec 08, 2020H.C. WainwrightBuyBuyHold

BioCryst Pharmaceuticals's last stock rating was published by Piper Sandler on Nov 04, 2024. The company gave BCRX a "Overweight" rating, the same as its previous rate.

BioCryst Pharmaceuticals Financial Forecast

BioCryst Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue---------$86.74M$82.49M$68.78M$79.55M$75.83M$65.53M$49.92M$47.16M$40.99M$49.96M$19.06M$4.02M$6.10M$2.87M$4.82M$39.73M$1.77M$1.45M$5.89M$3.98M$9.44M
Avg Forecast$145.89M$136.10M$130.57M$119.77M$128.65M$113.99M$98.30M$85.62M$89.97M$86.06M$81.42M$71.69M$75.23M$74.78M$63.33M$51.36M$51.06M$40.20M$28.11M$8.83M$14.74M$3.60M$2.25M$4.29M$9.88M$2.96M$2.02M$3.11M$2.91M$8.94M
High Forecast$151.59M$141.41M$135.67M$124.06M$132.91M$115.21M$98.30M$85.62M$94.32M$86.06M$84.60M$74.49M$78.17M$74.78M$63.33M$51.36M$51.06M$40.20M$28.11M$8.83M$14.74M$3.60M$2.25M$4.29M$9.88M$2.96M$2.02M$3.11M$3.49M$10.73M
Low Forecast$140.12M$130.71M$125.40M$115.46M$125.20M$112.78M$98.30M$85.62M$86.55M$86.06M$78.20M$68.85M$72.25M$74.78M$63.33M$51.36M$51.06M$40.20M$28.11M$8.83M$14.74M$3.60M$2.25M$4.29M$9.88M$2.96M$2.02M$3.11M$2.32M$7.15M
# Analysts11126334756322223456999988881018
Surprise %---------1.01%1.01%0.96%1.06%1.01%1.03%0.97%0.92%1.02%1.78%2.16%0.27%1.69%1.27%1.12%4.02%0.60%0.72%1.89%1.37%1.06%

BioCryst Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 7 analysts is $89.97M, with a low forecast of $86.55M, and a high forecast of $94.32M. BCRX's average Quarter revenue forecast represents a 3.72% increase compared to the company's last Quarter revenue of $86.74M (Sep 23).

BioCryst Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11126334756322223456999988881018
EBITDA---------$-7.74M$-16.95M$-25.04M$-43.61M$-15.69M$-34.11M$-49.90M$3.42M$-44.46M$-29.50M$-51.20M$-54.70M$-42.71M$-35.51M$-34.33M$650.00K$-34.37M$-34.41M$-28.15M$-23.37M$-11.95M
Avg Forecast$-106.70M$-99.53M$-95.49M$-87.59M$-94.09M$-83.37M$-71.90M$-29.84M$-65.80M$-62.94M$-59.55M$-31.92M$5.65M$-57.39M$-35.72M$-39.41M$-39.19M$-30.85M$-21.57M$-34.13M$-11.31M$-2.77M$-1.73M$-34.33M$-7.58M$-2.27M$-1.55M$-27.11M$-14.76M$-11.28M
High Forecast$-102.48M$-95.60M$-91.71M$-84.44M$-91.56M$-82.48M$-71.89M$-23.87M$-63.30M$-62.94M$-57.19M$-25.53M$6.78M$-57.39M$-28.57M$-39.41M$-39.19M$-30.85M$-21.57M$-27.31M$-11.31M$-2.77M$-1.73M$-27.47M$-7.58M$-2.27M$-1.55M$-21.69M$-11.81M$-9.03M
Low Forecast$-110.87M$-103.42M$-99.22M$-90.73M$-97.21M$-84.26M$-71.90M$-35.81M$-68.98M$-62.94M$-61.87M$-38.30M$4.52M$-57.39M$-42.86M$-39.41M$-39.19M$-30.85M$-21.57M$-40.96M$-11.31M$-2.77M$-1.73M$-41.20M$-7.58M$-2.27M$-1.55M$-32.53M$-17.71M$-13.54M
Surprise %---------0.12%0.28%0.78%-7.72%0.27%0.96%1.27%-0.09%1.44%1.37%1.50%4.84%15.44%20.53%1.00%-0.09%15.11%22.21%1.04%1.58%1.06%

2 analysts predict BCRX's average Quarter EBITDA for Mar 22 to be $-39.41M, with a high of $-39.41M and a low of $-39.41M. This is -1250.78% lower than BioCryst Pharmaceuticals's previous annual EBITDA (Dec 21) of $3.42M.

BioCryst Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11126334756322223456999988881018
Net Income---------$-36.15M$-75.33M$-53.33M$-71.54M$-42.52M$-58.86M$-74.20M$-17.78M$-58.80M$-43.20M$-64.28M$-60.49M$-46.12M$-38.61M$-37.60M$-2.62M$-37.59M$-37.63M$-31.05M$-25.78M$-14.22M
Avg Forecast$-2.07M$-10.35M$-16.55M$-21.04M$-15.52M$-14.25M$-35.79M$-37.47M$-50.87M$-50.69M$-48.42M$-40.07M$-29.34M$-58.92M$-62.32M$-74.83M$-60.90M$-60.43M$-48.23M$-42.86M$-51.81M$-52.64M$-52.75M$-37.60M$-52.98M$-66.06M$-63.99M$-29.90M$-16.28M$-13.43M
High Forecast$-1.96M$-9.81M$-15.70M$-20.48M$-1.94M$-13.52M$-33.95M$-29.97M$-29.67M$-48.08M$-45.93M$-32.06M$-23.47M$-58.92M$-49.86M$-74.83M$-60.90M$-60.43M$-48.23M$-34.28M$-51.81M$-52.64M$-52.75M$-30.08M$-52.98M$-66.06M$-63.99M$-23.92M$-13.02M$-10.74M
Low Forecast$-2.17M$-10.87M$-17.39M$-21.59M$-31.04M$-14.98M$-37.61M$-44.96M$-80.55M$-53.27M$-50.88M$-48.08M$-35.20M$-58.92M$-74.79M$-74.83M$-60.90M$-60.43M$-48.23M$-51.43M$-51.81M$-52.64M$-52.75M$-45.12M$-52.98M$-66.06M$-63.99M$-35.88M$-19.54M$-16.11M
Surprise %---------0.71%1.56%1.33%2.44%0.72%0.94%0.99%0.29%0.97%0.90%1.50%1.17%0.88%0.73%1.00%0.05%0.57%0.59%1.04%1.58%1.06%

BioCryst Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BCRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

BioCryst Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11126334756322223456999988881018
SG&A---------$50.65M$51.00M$47.87M$50.15M$36.92M$38.02M$34.28M$35.39M$34.99M$26.32M$22.11M$20.99M$17.20M$13.88M$15.87M$10.49M$11.73M$8.66M$6.24M$7.61M$3.06M
Avg Forecast$191.52M$178.66M$171.40M$157.22M$168.88M$149.64M$129.05M$12.89M$118.11M$112.97M$106.88M$13.78M$58.39M$98.17M$40.25M$67.42M$67.03M$52.77M$36.90M$11.59M$19.35M$4.73M$2.96M$5.63M$12.96M$3.89M$2.65M$4.08M$3.81M$2.89M
High Forecast$199.00M$185.64M$178.10M$162.86M$174.48M$151.24M$129.05M$15.47M$123.81M$112.97M$111.06M$16.54M$70.07M$98.17M$48.30M$67.42M$67.03M$52.77M$36.90M$11.59M$19.35M$4.73M$2.96M$5.63M$12.96M$3.89M$2.65M$4.08M$4.58M$3.47M
Low Forecast$183.94M$171.59M$164.62M$151.57M$164.35M$148.05M$129.05M$10.31M$113.62M$112.97M$102.65M$11.03M$46.71M$98.17M$32.20M$67.42M$67.03M$52.77M$36.90M$11.59M$19.35M$4.73M$2.96M$5.63M$12.96M$3.89M$2.65M$4.08M$3.05M$2.31M
Surprise %---------0.45%0.48%3.47%0.86%0.38%0.94%0.51%0.53%0.66%0.71%1.91%1.08%3.63%4.69%2.82%0.81%3.02%3.27%1.53%1.99%1.06%

BioCryst Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $118.11M, based on 7 Wall Street analysts, with a range of $113.62M to $123.81M. The forecast indicates a 133.19% rise compared to BCRX last annual SG&A of $50.65M (Sep 23).

BioCryst Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11126334756322223456999988881018
EPS---------$-0.19$-0.40$-0.28$-0.38$-0.23$-0.32$-0.40$-0.10$-0.33$-0.24$-0.36$-0.34$-0.26$-0.24$-0.24$-0.02$-0.34$-0.34$-0.28$-0.26$-0.19
Avg Forecast$-0.01$-0.05$-0.08$-0.10$-0.07$-0.07$-0.17$-0.21$-0.25$-0.24$-0.23$-0.30$-0.17$-0.29$-0.34$-0.36$-0.29$-0.29$-0.23$-0.27$-0.25$-0.26$-0.26$-0.24$-0.26$-0.32$-0.31$-0.27$-0.12$-0.17
High Forecast$-0.01$-0.05$-0.08$-0.10$-0.01$-0.07$-0.16$-0.20$-0.14$-0.23$-0.22$-0.28$-0.16$-0.29$-0.34$-0.36$-0.29$-0.29$-0.23$-0.27$-0.25$-0.26$-0.26$-0.24$-0.26$-0.32$-0.31$-0.27$-0.10$-0.14
Low Forecast$-0.01$-0.05$-0.08$-0.10$-0.15$-0.07$-0.18$-0.22$-0.39$-0.26$-0.25$-0.31$-0.17$-0.29$-0.34$-0.36$-0.29$-0.29$-0.23$-0.27$-0.25$-0.26$-0.26$-0.24$-0.26$-0.32$-0.31$-0.27$-0.14$-0.20
Surprise %---------0.78%1.71%0.94%2.28%0.81%0.93%1.10%0.33%1.13%1.03%1.35%1.35%1.02%0.94%0.99%0.08%1.06%1.10%1.03%2.17%1.12%

According to undefined Wall Street analysts, BioCryst Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BCRX previous annual EPS of $NaN (undefined).

BioCryst Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
XFORX4 Pharmaceuticals$0.74$3.67395.95%Buy
PDSBPDS Bio$1.96$9.00359.18%Buy
IMUXImmunic$1.09$5.00358.72%Buy
INMBINmune Bio$4.98$22.00341.77%Buy
KZRKezar Life Sciences$6.52$17.50168.40%Buy
VKTXViking Therapeutics$46.70$97.80109.42%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
AXSMAxsome Therapeutics$93.51$133.0042.23%Buy
MCRBSeres Therapeutics$0.88$1.2542.05%Buy
ATRAAtara Biotherapeutics$10.35$14.0035.27%Sell
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
BCRXBioCryst Pharmaceuticals$7.49$9.0020.16%Buy
AVXLAnavex Life Sciences$9.21$11.0019.44%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy
TGTXTG Therapeutics$33.57$23.75-29.25%Buy

BCRX Forecast FAQ

Is BioCryst Pharmaceuticals a good buy?

Yes, according to 15 Wall Street analysts, BioCryst Pharmaceuticals (BCRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 80.00% of BCRX's total ratings.

What is BCRX's price target?

BioCryst Pharmaceuticals (BCRX) average price target is $9 with a range of $7 to $11, implying a 18.89% from its last price of $7.57. The data is based on 15 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will BioCryst Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for BCRX stock, the company can go up by 18.89% (from the last price of $7.57 to the average price target of $9), up by 45.31% based on the highest stock price target, and down by -7.53% based on the lowest stock price target.

Can BioCryst Pharmaceuticals stock reach $11?

BCRX's average twelve months analyst stock price target of $9 does not support the claim that BioCryst Pharmaceuticals can reach $11 in the near future.

What are BioCryst Pharmaceuticals's analysts' financial forecasts?

BioCryst Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $426.56M (high $432.04M, low $421.9M), average EBITDA is $-279M (high $-270M, low $-289M), average net income is $-103M (high $-79.386M, low $-129M), average SG&A $460.46M (high $470.23M, low $451.76M), and average EPS is $-0.526 (high $-0.437, low $-0.624). BCRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $532.32M (high $552.74M, low $511.7M), average EBITDA is $-389M (high $-374M, low $-404M), average net income is $-50.003M (high $-47.961M, low $-52.027M), average SG&A $698.8M (high $725.6M, low $671.72M), and average EPS is $-0.242 (high $-0.232, low $-0.251).

Did the BCRX's actual financial results beat the analysts' financial forecasts?

Based on BioCryst Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $331.41M, beating the average analysts forecast of $329.13M by 0.69%. Apple's EBITDA was $-104M, missing the average prediction of $-220M by -52.90%. The company's net income was $-227M, beating the average estimation of $-190M by 19.20%. Apple's SG&A was $213.89M, missing the average forecast of $351.75M by -39.19%. Lastly, the company's EPS was $-1.18, beating the average prediction of $-1.024 by 15.28%. In terms of the last quarterly report (Sep 2023), BioCryst Pharmaceuticals's revenue was $86.74M, beating the average analysts' forecast of $86.06M by 0.79%. The company's EBITDA was $-7.737M, missing the average prediction of $-62.94M by -87.71%. BioCryst Pharmaceuticals's net income was $-36.149M, missing the average estimation of $-50.692M by -28.69%. The company's SG&A was $50.65M, missing the average forecast of $112.97M by -55.17%. Lastly, the company's EPS was $-0.19, missing the average prediction of $-0.245 by -22.45%